POSA57 Axicabtagene Ciloleucel and Tisagenlecleucel for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis
Abstract
Authors
M Bastos-Oreiro A de las Heras M Presa MÁ Casado C Pardo V Martín-Escudero A Sureda